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Background: Besides the pathological states, diabetes mellitus may also alter the hepatic biotransformation of
pharmaceutical agents. It is advantageous to understand the effect of diabetes on the pharmacokinetic of drugs.
The objective of this study was to define the pharmacokinetic changes of tramadol and its main metabolites after
in vivo intraperitoneal administration and ex vivo perfused liver study in diabetic rat model.
Tramadol (10 mg/kg) was administered to rats (diabetic and control groups of six) intraperitoneally and blood
samples were collected at different time points up to 300 min. In a parallel study, isolated liver perfusion was done
(in diabetic and control rats) by Krebs-Henseleit buffer (containing 500 ng/ml tramadol). Perfusate samples were
collected at 10 min intervals up to 180 min. Concentration of tramadol and its metabolites were determined by HPLC.
Results: Tramadol reached higher concentrations after i.p. injection in diabetics (Cmax of 1607.5 ± 335.9 ng/ml)
compared with control group (Cmax of 561.6 ± 111.4). M1 plasma concentrations were also higher in diabetic rats
compared with control group. M2 showed also higher concentrations in diabetic rats. Comparing the concentration
levels of M1 in diabetic and control perfused livers, showed that in contrast to intact animals, the metabolic ratios of
M1 and M5 (M/T) were significantly higher in diabetic perfused liver compared to those of control group.
Conclusions: The pharmacokinetic of tramadol and its three metabolites are influenced by diabetes. As far as M1 is
produced by Cyp2D6, its higher concentration in diabetic rats could be a result of induction in Cyp2D6 activity, while
higher concentrations of tramadol can be explained by lower volume of distribution.Introduction
The capacity of organisms to eliminate xenobiotics such
as pharmaceutical drugs and environmental pollutants
from their body is subject to change. One of the best-
known effective factors is the genetic variation of drug
metabolizing enzymes and transporters. Numerous gen-
etic polymorphisms have been reported with cytochrome
P450 (P450s) [1]. In addition to the genetic background,
xenobiotic-induced transcriptional activation or deactiva-
tion (i.e. induction or inhibition) has been documented in
large numbers and drawing many researchers’ attention
in order to avoid unfavorable drug–drug interactions
and side effects of therapeutic drugs [2]. Physiological and* Correspondence: rouini@tums.ac.ir
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reproduction in any medium, provided the orpathophysiological conditions also affect the activity of
P450s and other enzymes. Obesity and diabetes are world-
wide concerns as risk factors for metabolic syndromes in
the liver [3].
Diabetes mellitus, a disease with wide prevalence in
humans, involves many complications including micro-
and macro angiopathy as well as neuropathy, which in
turn leads to increase the incidence of many diseases.
Besides these pathological states, it is believed that pos-
sible diabetes-induced alterations in the hepatic bio-
transformation of pharmaceutical agents could also pose
additional health risk because of dangerous side effects due
to drug toxicity [4]. Considering the number of diabetic pa-
tients and their increased opportunities for drug therapy
compared to healthy subjects, it is of great interest to
understand the effect of this disease on drug metabolism.
Several chemicals have been used for induction of
insulin-dependent diabetes mellitus in animal models,
principally alloxan, streptozotocin and zinc chelators [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tural alterations in pancreatic beta cells (total degranula-
tion) within 48 h after administration and last up to
4 months [5].
In rat models of diabetes mellitus induced by strep-
tozotocin (DMIS) some physiological changes including a
decrease in bile flow rate [6], hepatotoxicity [7], impaired
renal function [8,9], disorders of the gastrointestinal tract
and reductions in protein binding of drugs due to elevated
plasma fatty acid level and/or glycosylation of plasma pro-
teins [9], have been reported. Glucuronidation and sul-
fation were also strongly affected in DMIS rats [10].
Recently, it was shown that the expression of CYP1A1,
2A1, 2B1, 2C12, 2E1, 3A4, 4A1 and/or 4A2 were appar-
ently increased in DMIS rats [11-14]. However, CYP2C11,
2C13, 2A2 and 3A2 were suppressed [12].
Tramadol hydrochloride (T) is a centrally acting anal-
gesic with efficacy and potency ranging between weak
opioids and morphine. The drug is mostly eliminated via
biotransformation in the liver in two main pathways in-
cluding O-demethylation to O-desmethyltramadol (M1)
(the pharmacologically active metabolite) by isoenzyme
cytochrome P450 2D6 (CYP2D6) and N-demethylation
to N-desmethyltramadol (M2) by cytochromes P450 2B6
(CYP2B6) and 3A4 (CYP3A4) [15]. These primary me-
tabolites may be further metabolized to three additional
secondary metabolites namely, N, N-didemethyltramadol
(M3), N, N, O-tridesmethyltramadol (M4) and N, O-
desmethyltramadol (M5). The O-desmethylated metabo-
lites are then further conjugated with glucuronic acid
and sulfate before excretion in urine [15].
Recently, tramadol was suggested as an effective oral
medication to alleviate pain in diabetic painful neuropathy
(DPN) [16,17] and the dose-dependent lowering effect of
tramadol on the plasma glucose levels of DMIS rats was
also reported by Cheng et al. [18]. Although tramadol is
known to be effective for the symptomatic relief of DPN,
little definitive data is available concerning the effects
of diabetes on hepatic drug metabolism and pharmaco-
kinetics of this compound. Moreover, the results of those
studies are not equivocal and are often contradictory.
The objective of this study was to investigate the phar-
macokinetic changes of tramadol and its main metabolites
after in vivo intraperitoneal administration and ex vivo
perfused liver study in the DMIS rat model.
Materials and methods
Materials
The pure substances of tramadol, M1, M2, M5 and cis-
tramadol as internal standard (Figure 1) were kindly
supplied by Grǖnenthal (Achen, Germany). All other
chemicals were supplied by Merck (Darmstadt, Germany).
Water used in all experiments was of Direct-QW quality
(Millipore, France).Animals
Male Sprague–Dawley rats of 7 weeks old (weighing 250–
300 g) were maintained in a clean room with 12 h light–
dark cycle, controlled temperature environment between
20 and 23°C, a relative humidity of 50% and free access to
standard laboratory chow and water. The study was ap-
proved by the Institutional Review Board of Pharmaceu-
tical Research Centre of Tehran University of Medical
Sciences. The animals were randomly divided into two ex-
perimental groups including control and DMIS rats.
Induction of diabetes
The animals were made diabetic with a single intravenous
injection of streptozotocin (Sigma, USA). Freshly prepared
streptozotocin (60 mg/kg) in 0.9% saline containing 0.01 M
sodium citrate (pH adjusted to 4.5) was administered once
to the overnight- fasted rats via the tail vein [19]. An equal
volume of a citrate buffer of pH 4.5 (0.3 ml) was injected
to the control rats. On day 7 after intravenous adminis-
tration of streptozotocin (rat models of DMIS) or a cit-
rate buffer (controls for rat model of DMIS), non-fasting
blood glucose levels of rats were measured using the Accu-
Chek ActiveW (Roche Diagnostics, Basel, Switzerland). The
diabetic state was confirmed by glucose levels exceeding
200 mg/dl.
Intact diabetic rat study
At seventh day after the beginning of treatment with
streptozotocin (DMIS rats), the femoral vein of one leg
of DMIS and control rats were cannulated with previ-
ously heparinized intravenous 16–18 gauge catheter while
each rat was under ketamine anesthesia using an intraper-
itoneal injection of xylazine/ketamine (15/75 mg/kg).
Tramadol was administered intraperitoneally as 10 mg/kg,
diluted in normal saline. The animals were kept under
anesthesia until the end of the experiment. Approximately,
200 μl of venous blood samples were collected in heparin-
ized tubes at: 0 (blank); 7.5, 15, 30, 45, 60, 90, 120, 165,
210, 255 and 300 min after tramadol administration.
Blood samples were immediately centrifuged for 20 min
at 1800 g and the plasma samples were stored at -80°C
until HPLC analysis. A 250 μl of heparinized normal sa-
line (15 units/ml) was used to flush the cannula to prevent
blood clotting. At the end of the study, animals were
sacrificed by cervical dislocation.
Isolated liver perfusion study
The isolated liver perfusion study was also conducted in
the DMIS and control rats. Animals were anesthetized
using an intraperitoneal injection of xylazine/ketamine
(15/75 mg/kg). The portal vein and superior vena cava
were catheterized with an intravenous 16–18 gauge cath-
eter, respectively. 500 units of heparin were injected into
the inferior vena cava. Freshly prepared Krebs-Henseleit
Figure 1 Metabolic pathway of tramadol.
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1.19 mm KH2PO4, 1.18 mm MgSO4 and 25 mm Na
HCO3, equilibrated with 95% O2/ 5% CO2, pH 7.4) (con-
taining 500 ng/ml tramadol) was passed through the portal
vein with a constant flow rate of 10 ml/min using a peristal-
tic pump. By this method, perfusion medium passed
through the liver and then collected from the superior vena
cava [20]. The total volume of the reservoir was 200 ml.
The temperature (37°C), pH (7.4) and perfusion pressure
(14 mmHg) were periodically monitored and kept un-
changed through the study. Liver variability was proved by
monitoring the liver enzymes activities (AST and ALT).
Perfusate samples were collected at 10 min intervals up to
180 min.
Analytical method
Tramadol, M1, M2 and M5 concentration in rat plasma
samples were determined by a previously described HPLC
method [21]. Briefly, all analytes were extracted with
ethylacetate and injected to a Knauer high-performanceliquid chromatography (Berlin, Germany), equipped with a
low-pressure gradient HPLC pump, a fluorescence detector,
a Rheodyne injector with a 100 μL loop and an online
degasser. Excitation and emission wavelength were 200 nm
and 301 nm respectively. Separation was achieved by
a Chromolith™ Performance RP-18e 100 × 4.6 mm
column (Merck, Darmastadt, Germany) protected by a
Chromolith™ guard cartridge RP-18e 5 × 4.6 mm. A meth-
anol: water (adjusted to pH of 2.5 by phosphoric acid) mix-
ture (19:81, v/v) at flow rate of 2 ml/min was used
as mobile phase. Data acquisition was carried out by using
ChromGate chromatography software (Knauer, Berlin,
Germany).
Pharmacokinetic analysis
The pharmacokinetics of tramadol and its metabolites
were determined by non-compartmental analysis using
MicrosoftW EXCEL under Windows XP in both intact
animal and isolated rat liver studies. Maximum plasma
and perfusate concentrations (Cmax) of analytes and their
Figure 2 Plasma concentration-time profile of tramadol and M1 in intact control and diabetic rats after receiving a 10 mg/kg of
tramadol intraperitoneally (n = 6 in each group, data are presented as mean ± SE).
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Elimination rate constant (β) was estimated as the abso-
lute value of the slope of least-square linear regression
of the terminal phase of the logarithmic concentration–
time curves. The terminal half-life (t1/2) was calculated
as 0.693/β. The area under the concentration versus
time curve was calculated by the trapezoidal rule for the
duration of sampling or last quantifiable concentration
and extrapolated from the last point to infinity with β.
Plasma clearance for tramadol (CL/F) was calculated as
Dose/AUC0–∞. Metabolic ratios for AUCs or concentra-
tions were calculated by dividing the AUC0–t or concen-
trations of the metabolite by that of tramadol for plasma
and perfusate samples.Figure 3 Plasma concentration-time profile of M2 and M5 in intact co
intraperitoneally (n = 6 in each group, data are presented as mean ±Statistical evaluation
Data was expressed as mean ± SD. To compare the phar-
macokinetic parameters of tramadol and its metabolites in
DMIS rats and control group, an unpaired t-test was used
for all parameters except Tmax, with which a nonparamet-
ric Wilcoxon two-sample test was used. A p-value of less
than 0.05 was considered to be statistically significant.
Results and discussion
Studies showed that pharmacokinetic parameters of drugs
can change by diabetes mellitus [22,23]. It has been sug-
gested that plasma protein binding of drugs may change
because of change in plasma fatty acid levels [9]. More-
over, an intracellular dehydration has been observed inntrol and diabetic rats after receiving a 10 mg/kg of tramadol
SE).
Table 1 Pharmacokinetic parameters of tramadol in diabetic and control rats
Parameter AUC 0-300min (ng.min/ml) AUC 0-∞ (ng.min/ml) Kel (1/min) App. Clearance (ml/min)
Control Diabetic Control Diabetic Control Diabetic Control Diabetic
Mean 88879.2 292661.1 133344.4 548924.4 0.0036 0.0026 22.3 5.5
P Value <0.05 <0.05 >0.05 <0.05
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may affect the distribution of drugs in the body.
It has also been reported that cardiac index and the
blood flow rate to the diaphragm, abdominal wall and
kidney elevate in male Sprague-Dawley DMIS and
Carworth Farms E (CFE) rats [25,26]. An increase in
most cytochrome p450 isoenzymes activity has also been
reported resulting in elevation of metabolites levels in
diabetic rats [27].
Tramadol is quickly and almost entirely absorbed after
an oral administration in human whereas its mean abso-
lute bioavailability is reported to be only 65–70% as a re-
sult of the first-pass hepatic metabolism. The high total
distribution volume of around 300 L after oral administra-
tion in human is caused by its high tissue affinity and dis-
tribution in fat tissues [28]. An enormous amount of
tramadol is rapidly metabolized to three main metabolites
in Liver. The principal metabolic pathways, O- and N-
desmethylation, involve cytochrome P-450 isoenzyme 2D6,
2B6 and 3A4, respectively. The primary metabolites O-
desmethyltramadol (M1) and N-desmethyltramadol (M2)
may be further metabolized to N, O-didesmethyltramadol
(M5). Ten to thirty percent of the parent drug is excreted
unchanged in the urine. Tramadol and its metabolites are
almost completely excreted via the kidneys and their biliary
excretion is negligible [29].
Animal studies for diabetes especially in rats and mice
have been commonly applied streptozocin to provide
type 1 diabetes. It has been reported that intravenous
administration of a dose ranging from 25 to 100 mg/kg
STZ could successfully induce a dose dependent hyper-
glycemia in rats [30]. In this study, we used a single
60 mg/kg dose of STZ intravenously in order to induce
the diabetes in rats.
Intact animals
Six rats completed the study in each group. Mean body
weight of rats in two study groups were not statistically
different at the beginning (285 ± 12 vs. 295 ± 16 grams in
control and treatment groups respectively, p > 0.05). WhileTable 2 AUC 0-300min (ng.min/ml) of tramadol metabolites; M1
Parameter M1
Control Diabetic Con
Mean 70835.2 124988.4 2244
P Value <0.05rats in treatment group showed a significant decrease in
their body weight during 7 days of diabetes induction (295 ±
16 vs. 235 ± 11 grams respectively, p < 0.05), no significant
changes was observed in body weight of control
group animals during this period. Plasma glucose con-
centrations measured 7 days from the beginning of the
study were significantly increased in animals given
streptozotocin, 388.4 ± 164.4 mgdL-1 compared with the
controls, 102.8 ± 31.1 mgdL-1 (P < 0.05). Animal in treat-
ment group had much higher water consumption in com-
parison to control group. Plasma concentration-time
profiles of tramadol and M1 are presented in Figure 2 and
those of M2 and M5 in Figure 3 respectively. Calculated
pharmacokinetic parameters for Tramadol and metabo-
lites are presented in Tables 1 and 2 respectively.
After i.p. injection in intact rats, tramadol was ab-
sorbed rapidly in both groups and reached much higher
concentrations in diabetic in comparison to control
group with a Cmax of 561.6 ± 111.4 and 1607.5 ± 335.9
ng/ml in control and diabetic rats respectively (p < 0.05).
However the time to Cmax (Tmax) was longer in diabetics
compared to control group (36.1 ± 17.1 min vs. 18.2 ±
11.4 min in diabetic and control rats respectively). Much
higher area under plasma-concentration-time curve was
also observed in diabetics in comparison to control group
(292661.1 ± 49048.2 vs. 88879.2 ± 14483.4 ng.min.ml-1 re-
spectively, p < 0.05). The terminal phase of tramadol
plasma concentration-time profile in both groups showed
no significant difference in elimination rate constant
(0.0036 ± 0.0009 min-1 vs. 0.0026 ± 0.0008 min-1) in con-
trol and diabetic groups respectively, (p > 0.05).
It has been assumed that tramadol is metabolized much
more rapidly in animals than in humans, and M1, M2 and
M5 are the main metabolites in all species [31]. Our study
also confirms that M1, M2 and M5 are formed and M1 re-
mains the major metabolite in rat. However it is not clear
if the same enzymes in human and rat are responsible for
metabolite formation in these two spices. In the present
study, M1 remained the major metabolite of tramadol in
both diabetic and non-diabetic intact rats., M2, M5
M2 M5
trol Diabetic Control Diabetic
7.3 31947.2 14486.2 15505.6
>0.05 >0.05
Figure 4 The metabolic ratio for M1, M2 and M5 in intact control and diabetic rats.
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were higher in diabetic rats compared to control group
which resulted in significantly higher AUCs in diabetics
(124988.4 ± 33887.3 vs. 70835.2 ± 14341.5 ng.min.ml-1
in diabetic and control respectively). In both groups the
concentration of M1 reached to an almost constant
value in about 90 minutes after drug administration.
Similar to tramadol and M1, M2 showed higher concen-
trations in diabetics in comparison with control rats. The
concentration of M2 in DMIS and control rats was in-
creased up to last sampling point. However the increment
trend in M2 concentration was much higher in diabetics
resulted in marked increase in AUC of this metabolite in
diabetics. As mentioned, diabetic group showed higher
concentrations (almost 1.7 times in diabetic group afterFigure 5 Perfusate concentration-time profile of tramadol, M1 and M
presented as mean ± SE).300 min compared to control groups) and higher AUCs
(31947.2 ± 9923.4 vs. 22447.3 ± 4871.6 ng.min.ml-1) com-
pared to control group. In contrast to M2 and similar to
M1, the M5 concentrations reached to a plateau in both
groups almost 60 minutes after drug administration and
there was no significant differences between AUC of both
groups (15505.6 ± 2433.2 vs. 14486.2 ± 2119.4 in diabetic
and control respectively) (p > 0.05).
As it is clear from above explained data, the diabetes
has markedly influenced pharmacokinetic of tramadol
and its metabolites in rats. Figures 2 and 3 show that
tramadol, M1 and M2 have higher concentrations in dia-
betic compared to control rats. Considering M1 as major
metabolite and induction of its formation in diabetic
rats, a reduction in plasma levels and AUC of tramadol5 in control (A) and diabetic (B) isolated rat liver (n = 6, data are
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pectation, both AUC0-300min and AUC0-∞ of tramadol are
significantly higher in diabetic rats. To further pursue this
argument, the metabolic ratios were studied for all three
metabolites. Figure 4 shows that for all three metabolites,
the metabolic ratio is higher in control in comparison to
diabetic rats. These higher metabolic ratios in control rats
may be caused by higher plasma levels of metabolites or
lower tramadol plasma levels in control group. Lower
plasma levels of tramadol could be resulted either from
higher metabolism rate (contrary to our expectation) or
higher distribution volume of the drug in control rats.
Diabetes may change the pattern of distribution of
drugs in the body. Tramadol has a high volume of distri-
bution in man [28]. Any reduction in fat tissue (which
usually happens during diabetic state) may cause a re-
duction in volume of distribution of lipophilic drugs
such as tramadol. Considering higher lipophilicity of
tramadol compared to its metabolites and consequently
higher distribution in fat tissue, such a phenomenon may
also explain higher plasma concentration of tramadol in
diabetic rats. In addition, the higher production level of
alph1-acid glycoprotein, an acute-phase serum protein
which is prominent in tramadol protein binding, in dia-
betic condition may further cause in decrease of volume
of distribution and increase in plasma concentration of
tramadol in diabetic rats. In isolated liver perfusion study,
the metabolism of drugs could be investigated when to a
high extent the effect of drug binding and distribution vol-
ume has been excluded. To further study the metabolic
state of tramadol and clear the possible effect of distribu-
tion volume and protein binding on metabolite formation
and metabolic ratios, an isolated rat liver study was
performed in both normal and diabetic rat liver.
Isolated liver study
Six rats completed the study in each group. Similar to in-
tact groups, the body weight and blood glucose levels be-
tween two groups were significantly different (P < 0.05).
Perfusate sample concentrations of tramadol, M1 and M5
measured by HPLC in both groups. Similar to our previ-
ous study [20], M2 was not detected in isolated liver study
samples. Figure 5 represents perfusate concentration-time
profiles of tramadol, M1 and M5 in control and diabetic
isolated livers respectively.
Similar to our previous study [20], M1 was the main
metabolite formed in both diabetic and control livers
and M2 metabolite was not seen (at least in concentra-
tions higher than 2.5 ng/ml) in perfusion study. A com-
parison between concentration levels of M1 in diabetic
and control livers showed that in contrast to intact ani-
mals, the metabolic ratios of M1 and M5 (M/T) are sig-
nificantly higher in diabetic rats compared to those of
control group (Figures 4 and 5). This higher metabolicratio in diabetic livers is the consequence of higher me-
tabolite (M1 and M5) production, a result that could not
easily be concluded in intact animal data. So it could be
fulfilled that higher metabolic ratios in intact control rats in
comparison to intact diabetic rats could be resulted from
lower plasma levels of tramadol itself in control group (in-
stead of higher metabolite production) which most possibly
has been resulted from higher volume of distribution and
lower protein binding of tramadol. To confirm the exact
role of distribution volume and even protein binding on
tramadol concentration and their effects on metabolic ra-
tios in control and diabetic rats, the PK study of tramadol
after iv administration and calculation of exact volume of
distribution and clearance (instead of apparent Vd and Cl)
is recommended.
Conclusion
In conclusion, the results of this study show that the
pharmacokinetic of tramadol and its three metabolites
has been influenced by diabetic condition. The higher
concentration of M1 could be a result of induction of
tramadol to M1 formation pathway, while higher con-
centrations of tramadol itself can be explained by its
lower volume of distribution in diabetic rats.
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